Royalty Pharma Q4 Earnings Report: What Investors Need to Know
Benzinga Insights 8 months ago
Earnings
The earnings results for Royalty Pharma (NASDAQ:RPRX) for Q4 were made public on Wednesday, February 11, 2026 at 07:00 AM.
Here's a comprehensive overview of the announcement.
Earnings
Royalty Pharma beat estimated earnings by 10.53%, reporting an EPS of $1.47 versus an estimate of $1.33.
Revenue was up $28.00 million from the same period last year.
Performance in Previous Earnings
In the previous quarter, the company beat on EPS by $0.1, resulting in a 0.89% increase change in the share price the following day.
Here's a look at Royalty Pharma's past performance:
| Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|
| EPS Estimate | 1.07 | 1.05 | 0.950 | 1.05 |
| EPS Actual | 1.17 | 1.14 | 1.057 | 1.16 |
| Revenue Estimate | 779.42M | 690.73M | 724.69M | 743.60M |
| Revenue Actual | 609.00M | 579.00M | 568.00M | 594.00M |
To track all earnings releases for Royalty Pharma visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.